Analytical Data
-
基因名
HLA-A*02:01&B2M&EBV LMP2(FLYALALLL) Monomer
- Application
-
别名
HLA-A*0201 & B2M & EBV LMP2 (FLYALALLL)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&FLYALALLL
-
分子量
40-43 kDa and 10 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on the HLA-A*02:01/B2M/EBV LMP2 (FLYALALLL) monomeric recombinant protein is grounded in the need to understand the immune response to Epstein-Barr Virus (EBV), which is associated with various malignancies such as lymphomas and nasopharyngeal carcinoma. Human Leukocyte Antigen (HLA) class I molecules, particularly HLA-A*02:01, play a crucial role in presenting viral peptides to cytotoxic T lymphocytes, facilitating the immune system's ability to target and destroy infected cells. The EBV LMP2 (Latent Membrane Protein 2) serves as a critical antigen for T-cell recognition, and the specific peptide FLYALALLL is known to be presented by HLA-A*02:01. By developing a monomeric recombinant protein consisting of HLA-A*02:01, beta-2-microglobulin (B2M), and the EBV LMP2 peptide, researchers aim to study the structural and functional properties of this complex. Understanding the interactions of this monomeric protein can provide insights into the mechanisms of immune recognition and evasion by EBV, potentially leading to the development of therapeutic vaccines or immunotherapies that can enhance the body’s immune response against EBV-associated diseases. This research not only contributes to the fundamental understanding of HLA-peptide interactions but also holds the promise of improving clinical outcomes for patients affected by EBV-related malignancies.
